Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Resource Type

CF Research News

Authors

Koliarne Tong, Daniel Barker, Megan France, Lucy Burr, Hugh Greville, Simone Visser, Peter Middleton, Claire Wainwright, Douglas Dorahy, Peter Wark

References

J Cyst Fibros. 2019 Dec 15;S1569-1993(19)30985-3. doi: 10.1016/j.jcf.2019.12.006.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

adverse events [3]
CFTR modulator [4]
Exacerbations [5]
Ivacaftor [6]
Lumacaftor [7]
Lung function [8]

Date

Sunday, December 15, 2019

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [9]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/lumacaftorivacaftor-reduces-exacerbations-adults-homozygous

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-19-00347R2_FINAL_Wark_260620.pdf [2] https://pubmed.ncbi.nlm.nih.gov/31848044/ [3] https://www.ecfs.eu/research-article-keywords/adverse-events [4] https://www.ecfs.eu/research-article-keywords/cftr-modulator [5] https://www.ecfs.eu/research-article-keywords/exacerbations [6] https://www.ecfs.eu/research-article-keywords/ivacaftor [7] https://www.ecfs.eu/research-article-keywords/lumacaftor [8] https://www.ecfs.eu/research-article-keywords/lung-function [9] https://www.ecfs.eu/resource-guideline-type/other-guidelines